Abstract Number: 2980 • 2018 ACR/ARHP Annual Meeting
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Background/Purpose: Treatment options for myositis-associated interstitial lung disease (ILD) include corticosteroids (CS) in combination with or without cyclophosphamide (CY), calcineurin inhibitors (CNIs) such as cyclosporine…Abstract Number: 5L • 2017 ACR/ARHP Annual Meeting
Rapamycin Vs. Placebo for the Treatment of Inclusion Body Myositis: Improvement of the 6 Min Walking Distance, a Functional Scale, the FVC and Muscle Quantitative MRI
Background/Purpose: Inclusion body Myositis (IBM) is the most frequent myositis in patients over 50 years old. Conventional immunosuppressive drugs are today ineffective or even aggravate…Abstract Number: 2137 • 2017 ACR/ARHP Annual Meeting
Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are rare, autoimmune chronic muscle diseases of childhood with significant potential long-term morbidity. In this study we investigate associations…Abstract Number: 2145 • 2017 ACR/ARHP Annual Meeting
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Background/Purpose: CXCR3 is a chemokine receptor that plays an important role in T cell chemotaxis in human autoimmune diseases. CXCR3, which is activated by ligand…Abstract Number: 2166 • 2017 ACR/ARHP Annual Meeting
Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response
Background/Purpose: Despite the absence of specific guidelines or trials on intravenous immunoglobulins (IvIg) in patients with idiopathic inflammatory myopathies (IIM), the treatment is considered effective…Abstract Number: 2309 • 2016 ACR/ARHP Annual Meeting
Focal Myositis: New Insights on Diagnosis and Pathology
Background/Purpose: Due to the rarity of the entity, the literature on focal myositis (FM) fails to address important questions on its nosology, associated disorders, clinical…Abstract Number: 2315 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Background/Purpose: Clinical research is dependent on being able to recruit and enroll appropriate patients in sufficient numbers to make robust conclusions. For many diseases it…Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…Abstract Number: 302 • 2015 ACR/ARHP Annual Meeting
Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis
Background/Purpose: Sporadic Inclusion Body Myositis (sIBM) is a progressive, idiopathic inflammatory myopathy characterized by dysphagia, weakness of proximal and distal muscles and atrophy. This cross-sectional…Abstract Number: 2361 • 2015 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: a Randomized, Treatment Delayed-Start Trial
Background/Purpose: The aim of the study was to assess the effects of abatacept, a T cell blocking agent, on disease activity and on muscle biopsy…Abstract Number: 2375 • 2015 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermtomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Interstitial Lung Disease…Abstract Number: 2456 • 2015 ACR/ARHP Annual Meeting
Anti SRP+Ve Myositis in Childhood. Presentation and Physiotherapy Treatment of This Rare Childhood Myositis
Background/Purpose: Previously it was understood that all Myositis in childhood was Juvenile Dermatomyositis. More recently Myositis specific antibodies have been discovered and these appear to…Abstract Number: 1327 • 2014 ACR/ARHP Annual Meeting
Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis
Background/Purpose: Orbital myositis (OM), an inflammatory disease affecting the extra-ocular muscles, typically presents in the third decade. It more commonly affects females and is extremely…Abstract Number: 1263 • 2014 ACR/ARHP Annual Meeting
Evidence for the Involvement of NK Cells in Antisynthetase Syndrome
Background/Purpose Antisynthetase syndrome (aSS) is characterized by the association of interstitial lung disease and myositis with anti-tRNA-synthetase autoantibodies. Its pathogenesis remains unknown, especially regarding the…